Phase II trial of cediranib alone or cediranib and lenalidomide in iodine 131-refractory differentiated thyroid cancer
Study on Investigational Medications for Thyroid Cancer
Brief description of study.
The purpose of this study is to find out what effects (good and bad) cediranib alone or in combination with lenalidomide will have on thyroid cancer.
Detailed description of study
The purpose of this study is to find out what effects (good and bad) cediranib alone or in combination with lenalidomide will have on thyroid cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Thyroid Cancer
-
Age: 18 years - 100 years
-
Gender: All
The purpose of this study is to investigate the effects of investigational medications on thyroid cancer. Thyroid cancer is a type of cancer that starts in the thyroid gland, which is located in the neck and produces hormones that regulate metabolism. This study aims to understand both the positive and negative effects of the investigational medications when used alone or in combination.
Participants in this study may receive either one or both of the investigational medications. The study will monitor participants for any changes in their condition and any side effects they may experience. This information will help researchers learn more about the safety and effectiveness of the treatments.
- Who can participate: Specific eligibility criteria, including age and key factors, are not provided.
- Study details: Participants will be assigned to receive either one or both investigational medications. A placebo may be used, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or